Takhzyro (lanadelumab-flyo) — Point32Health
hereditary angioedema
Initial criteria
- Documented diagnosis of hereditary angioedema
- Patient age ≥ 2 years
- Prescribed by or in consultation with an allergist, hematologist, or immunologist
- Documentation that 'on-demand' therapy (e.g., icatibant, Kalbitor, Ruconest, Berinert) did not provide satisfactory control OR access to 'on-demand' therapy is limited
Reauthorization criteria
- Documented diagnosis of hereditary angioedema
- Patient age ≥ 2 years
- Prescribed by or in consultation with an allergist, hematologist, or immunologist
- Documentation of a positive clinical response as evidenced by one of the following: (a) improvement in severity and duration of attacks has been achieved and sustained OR (b) a decrease in attack frequency
- For patients who have been attack free for 12 months, provider attestation that consideration has been given to changing the patient to a dosing interval of 300 mg every 4 weeks
Approval duration
6 months